atazanavir (Reyataz®)

Reference No. 29

Publication date:

21/01/2009

Appraisal information

atazanavir (Reyataz®) capsule

Company:	Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category:	Infections
NMG meeting date:	12/11/2008
AWMSG meeting date:	10/12/2008

Submission Type:	Full Submission
Status:	Recommended
Advice No:	2308
Ministerial ratification:	19/01/2009

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ministerial
Ratification

AWMSG advice

Atazanavir (Reyataz®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-experienced patients, in accordance with British HIV Association (BHIVA) guidance. Atazanavir (Reyataz®) is not suitable for shared care within NHS Wales.

Final Appraisal Recommendation (FAR)

Download

atazanavir (Reyataz) 29 FAR